When Will Conexeu Sciences Inc. (NASDAQ:CNXU) Become Profitable?

We feel now is a pretty good time to analyse Conexeu Sciences Inc.'s (NASDAQ:CNXU) business as it appears the company may be on the cusp of a considerable accomplishment. Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company’s loss has recently broadened since it announced a US$3.9m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$14m, moving it further away from breakeven. Many investors are wondering about the rate at which Conexeu Sciences will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

According to some industry analysts covering Conexeu Sciences, breakeven is near. They expect the company to post a final loss in 2027, before turning a profit of US$38m in 2028. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 68%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving Conexeu Sciences' growth isn’t the focus of this broad overview, though, bear in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

See our latest analysis for Conexeu Sciences

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 6.5% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of Conexeu Sciences which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Conexeu Sciences, take a look at Conexeu Sciences' company page on Simply Wall St. We've also compiled a list of important factors you should look at:

1. Historical Track Record: What has Conexeu Sciences' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Conexeu Sciences' board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.